<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6355">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01661803</url>
  </required_header>
  <id_info>
    <org_study_id>acpm anesthesia.dhule.</org_study_id>
    <nct_id>NCT01661803</nct_id>
  </id_info>
  <brief_title>Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation</brief_title>
  <official_title>Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACPM Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACPM Medical College</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators can summarize intrathecal clonidine can potentiate bupivacaine thereby
      bringing about better quality and longer duration of analgesia, better sedation and better
      postoperative outcomes with minimal side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our Randomized controlled, double blind study involving 30 subjects in two groups; the
      investigators compared the safety, efficacy and quality of using intrathecal hyperbaric
      bupivacaine 0.5% and hyperbaric bupivacaine 0.5% with clonidine 1µg/kg in paediatric
      patients undergoing surgeries below T8 dermatome.

      American Society of Anesthesiologists (ASA) Grade I patients aged between 3-10 years were
      scheduled for the surgeries below T8 dermatome up to two hrs duration. The patients were
      randomly allocated in - Group A-who received 0.5%of hyperbaric Bupivacaine 0.4mg/kg for 5
      to15 kg or 0.3 mg/kg for more than 15 kg intrathecally.

      Group B-who received 0.5%of hyperbaric Bupivacaine 0.4mg/kg for 5 to15 kg or 0.3 mg/kg for
      more than 15 kg and 1µg/kg preservative free clonidine intrathecally.

      The patients studied across the group did not vary much with respect to age, weight and sex
      distribution.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Pediatric Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>group-A and group-B</arm_group_label>
    <description>Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for &gt;15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for &gt;15 with 1 mcg/kg preservative free clonidine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group-A and group--B</arm_group_label>
    <description>Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for &gt;15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for &gt;15 with 1 mcg/kg preservative free clonidine).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        prospective,randomized,double blind study cariied in 60 ASA grade 1 pediatric patients
        undergoing surgeries below T8 dermatome upto two hours duration.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA grade-1 physical status.

          2. weight 5-35kg

          3. age-3 to 10 yrs

        Exclusion Criteria:

          1. patients with known sensitivity to drugs to be used.

          2. gross spinal deformity

          3. patients in whom regional anesthesia is contraindicated.

          4. patients with peripheral neuropathy.

          5. patient with hemodynamic instability.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 9, 2012</lastchanged_date>
  <firstreceived_date>August 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ACPM Medical College</investigator_affiliation>
    <investigator_full_name>DR.NAGESH JAMBURE</investigator_full_name>
    <investigator_title>resident,anesthesia department,a.c.p.m.medical college,dhule,maharashtra,india</investigator_title>
  </responsible_party>
  <keyword>bupivacaine</keyword>
  <keyword>clonidine</keyword>
  <keyword>pediatric spinal</keyword>
  <keyword>efficacy</keyword>
  <keyword>duration</keyword>
  <keyword>quality</keyword>
  <keyword>side effects</keyword>
  <keyword>intrathecal bupivacaine alone</keyword>
  <keyword>bupivacaine plus clonidine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
